BenzingaBenzinga Korea 한국
BenzingaBenzinga Korea 한국
BenzingaBenzinga Korea 한국
토요일, 9월 19

Twist Bioscience Corp

TWSTNASDAQ
Trade with Public
Trade with Public
$166.99
11.437.35%
가까이에: Sep 18, 5:00 PM EST
$166.60
-0.39-0.23%
시간외: 6:31 PM EST
개요뉴스실적 전망이벤트목표가재무심리지분 현황비교옵션주식 보고서

Twist Bioscience Analyst Price Targets

Wall Street analyst price targets and consensus rating for Twist Bioscience (TWST).

Price Target Range — 11 Quarters

Analyst Consensus — 15 Analysts

11Buy
2Hold
2Sell
Consensus RatingBuy# Analysts15Avg. Consensus PT$79Upside to Avg. PT-52.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →
DateFirmAnalystActionRating ChangePrice Target
Sep 18, 2026BWS FinancialHamed KhorsandMaintainedSell$45
Sep 17, 2026Leerink PartnersPuneet SoudaPT RaiseOutperform$120→$160
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
BWS Financial Initiates Coverage On Twist Bioscience with Sell Rating, Announces Price Target of $45

BWS Financial analyst Hamed Khorsand initiates coverage on Twist Bioscience (NASDAQ:TWST) with a Sell rating and announces Price Target of $45.
Benzinga Newsdesk

PRO
UBS Initiates Coverage On Twist Bioscience with Neutral Rating, Announces Price Target of $144

UBS analyst Doug Schenkel initiates coverage on Twist Bioscience (NASDAQ:TWST) with a Neutral rating and announces Price Target of $144.
Benzinga Newsdesk

PRO
Piper Sandler Maintains Overweight on Twist Bioscience, Raises Price Target to $115

Piper Sandler analyst David Westenberg maintains Twist Bioscience (NASDAQ:TWST) with a Overweight and raises the price target from $85 to $115.
Benzinga Newsdesk

PRO
Baird Maintains Outperform on Twist Bioscience, Raises Price Target to $115

Baird analyst Catherine Ramsey maintains Twist Bioscience (NASDAQ:TWST) with a Outperform and raises the price target from $113 to $115.
Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on Twist Bioscience, Raises Price Target to $120

Canaccord Genuity analyst Kyle Mikson maintains Twist Bioscience (NASDAQ:TWST) with a Buy and raises the price target from $90 to $120.
Benzinga Newsdesk

PRO
Evercore ISI Group Downgrades Twist Bioscience to In-Line, Raises Price Target to $102

Evercore ISI Group analyst Vijay Kumar downgrades Twist Bioscience (NASDAQ:TWST) from Outperform to In-Line and raises the price target from $66 to $102.
Benzinga Newsdesk

데이터 및 API: Benzinga API · 주식 뉴스 API · 애널리스트 등급 API · 회사 로고 API

시장 데이터 제공 Benzinga API

BenzingaBenzinga Korea 한국

뉴스

파트너 / 기고자

벤징가 글로벌

© 2026 Benzinga | All Rights Reserved